Rituximab Resistance in Glomerular Diseases: A GlomCon Mini Review

0301 basic medicine human antichimeric antibodies 03 medical and health sciences rituximab resistance Nephrology Antidrug antibodies glomerular disease GlomCon Mini Review RC870-923 B-cell depletion therapy CD20 antigen Diseases of the genitourinary system. Urology
DOI: 10.1016/j.xkme.2024.100791 Publication Date: 2024-02-16T17:59:03Z
ABSTRACT
Resistance to rituximab B-cell depletion therapy is a clinically pertinent adverse sequela that can have significant implications for the treatment of immune-mediated glomerular diseases. The true incidence resistance remains unknown; however, it an increasingly recognized complication. typically presents with suboptimal response, rapid reconstitution, and relapsing disease course. Although diverse mechanisms resulting in are ongoing topics research, both primary secondary been identified as key catalysts. emergence human antichimeric antibodies (HACAs) major cause appears following repeated drug exposure. Frequently, HACAs develop setting underlying autoimmune contribute poor depletion, reduced therapeutic efficacy, enhanced clearance. clinical challenge necessitates heightened awareness among clinicians. Screening should be considered individuals response rituximab, more disease. Detection may guide alterations, including addition further immunosuppressive transitioning humanized depleting monoclonal antibody.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (24)
CITATIONS (2)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....